74,773 Shares in Upstream Bio, Inc. (NASDAQ:UPB) Acquired by Moody Aldrich Partners LLC

Moody Aldrich Partners LLC purchased a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 74,773 shares of the company's stock, valued at approximately $1,229,000. Moody Aldrich Partners LLC owned approximately 0.14% of Upstream Bio as of its most recent SEC filing.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. JPMorgan Chase & Co. began coverage on shares of Upstream Bio in a research note on Tuesday, November 5th. They issued an "overweight" rating and a $38.00 price target on the stock. Piper Sandler began coverage on shares of Upstream Bio in a research report on Tuesday, November 5th. They issued an "overweight" rating and a $75.00 price target for the company. TD Cowen assumed coverage on Upstream Bio in a research note on Tuesday, November 5th. They set a "buy" rating on the stock. Finally, William Blair began coverage on Upstream Bio in a research note on Tuesday, November 5th. They issued an "outperform" rating for the company.

Upstream Bio Stock Performance

Shares of UPB traded up $0.03 during mid-day trading on Wednesday, hitting $9.88. 51,888 shares of the company's stock were exchanged, compared to its average volume of 246,290. Upstream Bio, Inc. has a fifty-two week low of $9.29 and a fifty-two week high of $29.46. The company has a 50 day simple moving average of $17.01.

Upstream Bio (NASDAQ:UPB - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($6.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by ($6.38). The firm had revenue of $0.61 million during the quarter, compared to analyst estimates of $0.83 million. Equities research analysts forecast that Upstream Bio, Inc. will post -4.3 EPS for the current year.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.